Test Price
2,500 AED✅ Home Collection Available
📋 Results in 10 working days
Cancer Gene Any 3 Markers NGS Test in UAE2500 AED | DHA Licensed Laboratory
Executive Summary & Core Metrics
Clinical Performance & Service Framework
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO‑accredited NGS processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection for whole blood specimens; Secure Medical Courier Solid Tissue Specimen Retrieval for FFPE blocks. Available daily 8 AM – 11 PM.
- Clinical Guidance: Telephonic post‑test interpretation by a qualified specialist included with every report.
- Insurance & Billing: Direct billing verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The Cancer Gene Any 3 Markers NGS Test employs Illumina‑based next‑generation sequencing to analyse three clinically indicated genes for pathogenic variants associated with hereditary cancer syndromes. This targeted panel enables personalised risk stratification and therapeutic decision‑making in a single, high‑throughput workflow.
| Feature | Our Test | Closest Alternative |
|---|---|---|
| Precision | NGS with >99% analytical sensitivity for SNVs, indels, and copy number variants | Sanger sequencing (limited multiplex capacity) |
| Methodology | Illumina‑based NGS in ISO 9001:2015 accredited laboratory | PCR‑based hotspot panels |
| Turnaround Time | 10 working days | 15–20 working days |
Physician Insight & Safety Protocols
“Targeted NGS analysis of three cancer susceptibility genes enables precise variant detection for informed clinical decision‑making. A negative result does not eliminate hereditary risk and must be interpreted within the full clinical and family history context. Pre‑ and post‑test genetic counselling is integral to the testing pathway.” — Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology (DHA Registration ID: 61713011)
Advisory Notice
Medication & Clinical Advisory
Maintain all prescribed therapies unless directed otherwise by your treating physician. This molecular assay does not replace routine oncological surveillance, clinical examination, or ongoing treatment plans.
Exclusion Criteria & Emergency Red Flags
- Active severe infection or haemodynamic instability – defer collection until clinically stable.
- Known bone marrow aplasia may yield insufficient DNA from peripheral blood; consider FFPE or consult laboratory.
- For solid tumour FFPE blocks: the specimen must contain ≥10% tumour nuclei; otherwise the test may be cancelled and re‑biopsy required.
- Emergency Red Flags: New severe pain, unexplained fever, sudden neurological changes, or respiratory distress – seek immediate emergency care.
Patient FAQ & Clinical Guidance
1. What is the Cancer Gene Any 3 Markers NGS Test and what conditions does it address?
This targeted panel analyses three cancer‑related genes selected by your physician using next‑generation sequencing. It identifies inherited pathogenic variants that increase susceptibility to malignancies such as breast, ovarian, colorectal, prostate, and pancreatic cancers, depending on the genes ordered. The test achieves >99.9% analytical sensitivity for single nucleotide variants, small insertions/deletions, and copy number alterations.
2. How is the sample collected and what logistics are available?
Two pathways exist based on the required specimen. For haematological indications, 3 mL of whole blood in EDTA (lavender top) is collected via our VIP Mobile Phlebotomy service with temperature‑controlled cold‑chain transport, available daily from 8 AM to 11 PM. For solid tumours, an FFPE tissue block with ≥10% tumour content is retrieved via Secure Medical Courier Solid Tissue Specimen Retrieval. All logistics are ISO‑certified and tracked in real time.
3. How will I receive my results and what support is available after testing?
Results are delivered within 10 working days via a secure encrypted portal and a physical copy. Every report includes a telephonic post‑test consultation with our genetics specialist to explain findings, discuss clinical implications, and guide next steps including referral to oncology or genetic counselling services.
UAE Regulatory & Data Privacy Adherence
Your Data. Protected by UAE Law.
All genetic and personal data processed during this test is governed by Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols adhere to Federal Decree‑Law No. 4 of 2016 on Medical Liability. Testing is performed in an ISO 9001:2015 certified facility (Certificate No. INT/EGQ/2509DA/3139) with encrypted reporting and access controls.
A duly completed NGS Test Requisition Form (Form 40) is mandatory. For minor patients, guardian consent is required per UAE federal regulations.
Clinical & Logistical Metadata
| Test Name | Cancer Gene Any 3 Markers NGS Test |
| Price (AED) | 2500 AED |
| Turnaround Time | 10 working days |
| Sample Type / Matrix | Whole Blood (EDTA, Lavender Top) for haematological indications; FFPE Tissue Block (≥10% tumour nuclei) for solid tumours |
| Methodology Used | Illumina‑based Next‑Generation Sequencing (NGS) |
| ICD-10-CM Code | Z15.09 (Genetic susceptibility to other malignant neoplasm) |
| LOINC Code | 92981-5 (Genetic analysis NGS panel) |
| DHA Facility License & Address | DHA Facility License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
Preparation Required
[]
Medically Reviewed by Dr. Dr. Prabhakar Reddy Kalathoor
All content reviewed by qualified professionals for accuracy.
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians